ORBi Open Repository and Bibliography
(149.380 recursos)
In may 2007, the ULg's Administrative Board (joined in June 2007 by the FUSAGx) decided to create an institutional repository and defined a strong institutional self-archiving policy to increase the visibility, accessibility and impact of the University's publications (Board's decision).
This decision led to the official launch, in November 2008, of the ORBi platform including both the Academic Bibliography and the Institutional Repository of the Wallonia-Europe University Academy.
3.
Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation - SERVAIS, Sophie; Beguin, Yves; Baron, Frédéric
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for many patients suffering from hematological malignancies, severe hemoglobinopathies, bone marrow failures or severe primary immunodeficiencies. Graft rejection/failure (GF) is a life-threatening complication following allo-HSCT that is most commonly caused by the reactivity
of recipient T cells, natural killer (NK) cells or antibodies against donor grafted hematopoietic cells. The increasing use of allo-HSCT following reduced-intensity conditioning (RIC) and the increasing use of alternative donors (unrelated cord blood and human leukocyte antigen (HLA)-mismatched
donor) have resulted in higher frequency of GF.
Areas covered: This review describes the pathogenesis and current prevention and...
4.
Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. - JASPERS, Aurélie; Baron, Frédéric; WILLEMS, Evelyne; HAFRAOUI, Kaoutar; Vanstraelen, Gaëtan; Bonnet, Christophe; Beguin, Yves
Based on the impairment of erythropoietin production after allogeneic hematopoietic cell transplantation (HCT), we previously reported in a phase-2 trial that recombinant human erythropoietin (rhEPO) therapy was very efficient when started one month after transplantation. We also demonstrated that anemia after nonmyeloabalative (NM) HCT was less sensitive to rhEPO therapy than after conventional allogeneic HCT. This prompted us to confirm
these findings in a prospective randomised trial.
One hundred and thirty-one patients were randomised (1:1) between no treatment (arm 1) or erythropoietin (Neorecormon) at the dose of 500 U/kg/week (arm 2). Once the target Hb (13g/dL) has been attained, the dose...
1.
